company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18633500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18633500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4248800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4248800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14384700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4232300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,302500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10629900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3754800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,122000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,122000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3876800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,923800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2953000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2953000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2953000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1089700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.71
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1089700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.71
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1089700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2007.0,FY,2007-01-01,2007-12-31,2010-02-22 12:45:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.71
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20371900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20371900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4376700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4376700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15995200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6626400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8676300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1974000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17276700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1281500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-26100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1307600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,764300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2071900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2071900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2071900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1096200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.89
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1096200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.89
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1096200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,FY,2008-01-01,2008-12-31,2010-02-22 12:45:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.89
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5092400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,117100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5209500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1155200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1155200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4054300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1649200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,981000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1659400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4289600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-235300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-232800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,232800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-465600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-465600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-465600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1082800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.43
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1082800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.43
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1082800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.43
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q3,2008-07-01,2008-09-30,2009-10-30 13:15:47+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,5150400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5150400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1200900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalcostofrevenue,othercostofrevenue,Other Cost of Revenue,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1200900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3949500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1700100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,986500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,explorationexpense,Exploration Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,88900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2775500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1174000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-32300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-32300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1141700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,247500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,894200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincome,extraordinaryincome,"Extraordinary Income / (Loss), net",+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,894200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,894200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1016100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.88
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2008.0,Q2,2008-04-01,2008-06-30,2009-07-31 10:22:37+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11227000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5934200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1431300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1431300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4502900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1953300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1306700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,37900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3297900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1205000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-116000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-116000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1089000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,221800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,867200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,867200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,867200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1098338000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.88
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1098338000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.88
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1098338000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.82
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q4,2009-10-01,2009-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21836000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21836000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4247000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4247000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17589000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6892500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4416500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,692700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12001700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5587300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-229500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-229500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5357800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1029000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4328800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4328800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4328800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1098338000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.94
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1098338000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.94
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1098338000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.94
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,FY,2009-01-01,2009-12-31,2012-02-24 17:07:08+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.96
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5562000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5562000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1051900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1051900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4510100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1701800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1122100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,549800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3373700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1136400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-66900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-66900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1069500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,127700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,941800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,941800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,941800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3,2009-07-01,2009-09-30,2010-10-29 09:15:32+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10609000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15901800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2815700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2815700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13086100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4939200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3109800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,654800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8703800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4382300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-113500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-113500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4268800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,807200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3461600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3461600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3461600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.06
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.06
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1095100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q3YTD,2009-01-01,2009-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,947400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalcostofrevenue,othercostofrevenue,Other Cost of Revenue,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,947400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4345400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1708200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,marketingexpense,Marketing Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1040400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,explorationexpense,Exploration Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,depreciationexpense,Depreciation Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,105000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2853600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1491800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,24100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,24100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1515900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,309200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1206700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincome,extraordinaryincome,"Extraordinary Income / (Loss), net",+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1206700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincometocommon,preferreddividends,Preferred Stock Dividends Declared,-,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1206700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1138400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.06
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2,2009-04-01,2009-06-30,2009-07-31 10:22:37+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5047000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10339800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1763800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1763800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8576000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3237400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1987700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,105000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5330100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3245900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-46600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-46600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3199300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,679500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2519800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2519800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2519800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1138400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.26
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q2YTD,2009-01-01,2009-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.98
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5047000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5047000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,816400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,816400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4230600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1529200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,947300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2476500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1754100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-70700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-70700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1683400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,370300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1313100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1313100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1313100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1094300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1094300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1094300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2009.0,Q1,2009-01-01,2009-03-31,2010-04-30 10:09:16+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6187000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6187000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1232200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1232200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4954800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1988700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1438100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,79000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3505800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1449000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-39400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-39400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1409600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,240000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1169600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1169600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1169600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1105788000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1105788000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1105788000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q4,2010-10-01,2010-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23076000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23076000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4366200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4366200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18709800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7053400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4934200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,192000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12179600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6530200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-5000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6525200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1455700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5069500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5069500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5069500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1105788000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,4.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1105788000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1105788000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,FY,2010-01-01,2010-12-31,2013-02-21 10:28:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5654800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5654800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,987600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,987600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4667200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1694900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1219800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,59500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2974200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1693000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-21700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-21700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1671300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,368400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1302900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1302900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1302900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3,2010-07-01,2010-09-30,2010-10-29 09:15:32+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16889000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16889000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3134000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3134000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13755000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5064700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3496100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,113000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8673800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5081200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,34400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,34400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5115600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1215700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3899900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3899900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3899900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3YTD,2010-01-01,2010-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28116000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22823200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4565300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4565300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18257900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7018000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4802800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,150900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11971700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6286200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-81600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-81600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6204600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1437500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4767100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4767100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4767100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,5.41
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.41
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1104200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.35
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q3TTM,2009-10-01,2010-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.96
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5748700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5748700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1023900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1023900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4724800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1755400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1187200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,27300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2969900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1754900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-18400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-18400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1736500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,387600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1348900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1348900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1348900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.22
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.22
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.22
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2,2010-04-01,2010-06-30,2010-07-30 17:56:06+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11234200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11234200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2146400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2146400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9087800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3369800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2276300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,53500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5699600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3388200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,56100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,56100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3444300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,847300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2597000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2597000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2597000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.35
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.35
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.35
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2YTD,2010-01-01,2010-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.98
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28023200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalrevenue,otherrevenue,Other Revenue,+,credit,usd,-5292800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22730400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4629600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4629600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18100800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7024900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4705100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,641200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12371200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5729600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-126800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-126800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5602800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1196800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4406000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4406000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4406000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,5.09
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.09
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1105700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.03
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q2TTM,2009-07-01,2010-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.96
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22274500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22274500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4553100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4553100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17721400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6977700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4558300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,718900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12254900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5466500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-84300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-84300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5382200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1118400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4263800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4263800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4263800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1104500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.87
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1104500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.87
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1104500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.87
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1TTM,2009-04-01,2010-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.96
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5485500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5485500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1122500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1122500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4363000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1614400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1089100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,26200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2729700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1633300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,74500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,74500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1707800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,459700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1248100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1248100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1248100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1104500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1104500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1104500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2010.0,Q1,2010-01-01,2010-03-31,2011-04-29 12:57:48+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6046600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6046600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1321700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1321700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4724900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2133400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1355300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,167600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3656300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1068600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-26800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-26800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1041800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,183600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,858200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,858200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,858200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113923000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.77
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1113923000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.77
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1113923000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.77
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q4,2011-10-01,2011-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24286500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24286500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5067900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5067900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19218600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7879900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5408800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,401400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13690100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5528500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-179000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-179000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5349500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1001800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4347700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4347700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4347700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113923000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.9
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1113923000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.9
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1113923000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,FY,2011-01-01,2011-12-31,2014-02-19 13:34:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.9
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6147900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6147900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1338100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1338100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4809800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1917800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1280900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,25200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3223900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1585900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-83400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-83400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1502500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,266200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1236300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1236300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1236300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3,2011-07-01,2011-09-30,2011-10-28 15:35:38+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18239900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18239900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3746200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3746200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14493700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5746500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4053500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,233800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10033800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4459900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-152200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-152200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4307700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,818200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3489500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3489500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3489500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3YTD,2011-01-01,2011-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24426900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24426900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4978400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4978400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19448500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7735200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5491600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,312800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13539600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5908900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-191600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-191600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5717300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1058200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4659100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4659100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4659100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,4.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1113800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q3TTM,2010-10-01,2011-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6252800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6252800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1228000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1228000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5024800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2043000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1260600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,132300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3435900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1588900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-57600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-57600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1531300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,334000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1197300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1197300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1197300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2,2011-04-01,2011-06-30,2011-07-29 15:48:00+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12092000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12092000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2408100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2408100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9683900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3828700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2772600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,208600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6809900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2874000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-68800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-68800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2805200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,552000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2253200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2253200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2253200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.02
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.02
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.02
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2YTD,2011-01-01,2011-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.98
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23933800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23933800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4627900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4627900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19305900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7512300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5430500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,347100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13289900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6016000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-129900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-129900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5886100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1160400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4725700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4725700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4725700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,4.25
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.25
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1119000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q2TTM,2010-07-01,2011-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.25
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5839200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5839200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1180100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1180100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4659100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1785700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1512000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,76300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3374000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1285100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-11200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1273900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,218000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1055900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1055900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1055900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1111500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.95
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1111500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.95
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1111500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.95
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1,2011-01-01,2011-03-31,2011-04-29 12:57:48+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23429700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23429700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4423800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4423800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19005900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7224700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5357100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,242100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12823900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6182000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-90700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-90700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6091300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1214000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4877300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4877300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4877300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1111500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,4.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1111500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1111500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2011.0,Q1TTM,2010-04-01,2011-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5957400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5957400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1248300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1248300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4709100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1977500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1463100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,204000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3644600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1064500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-52000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-52000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1012500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,185200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,827300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,827300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,827300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113178000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.75
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1117294000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.74
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1114100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.75
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q4,2012-10-01,2012-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22603400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22603400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4796500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4796500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17806900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7513500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5278100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,281100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13072700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4734200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,674000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,674000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5408200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1319600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4088600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4088600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4088600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1113178000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.67
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1117294000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.66
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1114100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,FY,2012-01-01,2012-12-31,2015-02-19 16:02:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.67
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5443300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5443300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1203600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1203600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4239700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1757400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1342800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,53300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3153500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1086200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,788500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,788500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1874700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,548100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1326600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1326600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1326600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3,2012-07-01,2012-09-30,2012-10-26 15:24:11+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16646000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16646000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3548200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3548200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13097800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5536000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3815000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,77100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9428100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3669700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,726000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,726000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4395700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1134400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3261300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3261300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3261300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.92
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.92
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.92
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3YTD,2012-01-01,2012-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22692600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22692600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4869900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4869900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17822700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7669400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5170300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,244700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13084400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4738300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,699200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,699200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5437500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1318000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4119500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4119500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4119500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.69
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.69
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1124200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q3TTM,2011-10-01,2012-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.69
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5600700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5600700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1146700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1146700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4454000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1931100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1320700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3251800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1202200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-16500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-16500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1185700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,262100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,923600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,923600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,923600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.83
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.83
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.83
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2,2012-04-01,2012-06-30,2012-07-27 13:05:14+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11202700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11202700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2344600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2344600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8858100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3778600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2472200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,23800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6274600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2583500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-62500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-62500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2521000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,586300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1934700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1934700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1934700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.74
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.74
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.74
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2YTD,2012-01-01,2012-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.98
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23397200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23397200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5004400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5004400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18392800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7829800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5108400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,216600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13154800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5238000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-172700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-172700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5065300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1036100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4029200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4029200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4029200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.62
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.62
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q2TTM,2011-07-01,2012-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.62
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5602000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5602000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1197900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1197900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4404100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1847500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1151500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,23800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3022800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1381300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-46000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-46000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1335300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,324200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1011100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1011100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1011100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1111100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.91
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1111100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.91
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1111100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.91
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1,2012-01-01,2012-03-31,2012-04-30 15:25:52+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24049300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24049300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5085700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5085700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18963600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7941700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5048300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,348900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13338900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5624700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-213800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-213800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5410900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1108000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4302900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4302900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4302900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1111100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1111100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1111100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2012.0,Q1TTM,2011-04-01,2012-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5808800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5808800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1386500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1386500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4422300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1953600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1532500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,35400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3521500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,900800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,9100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,9100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,909900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,182400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,727500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,727500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,727500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1080874000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1084766000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1081900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q4,2013-10-01,2013-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23113100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23113100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4908100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4908100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18205000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7125600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5588400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,120600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12834600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5370400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,518900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,518900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5889300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1204500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4684800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4684800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4684800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1080874000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,4.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1084766000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.32
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1081900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,FY,2013-01-01,2013-12-31,2015-02-19 16:02:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5772600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5772600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1198100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1198100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4574500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1652400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1377400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3029800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1544700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-31300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-31300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1513400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,310300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1203100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1203100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1203100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3,2013-07-01,2013-09-30,2013-10-30 11:21:23+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17304300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17304300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3521600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3521600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13782700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5172000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4055900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,85200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9313100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4469600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,509800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,509800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4979400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1022100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3957300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3957300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3957300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.65
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.64
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.65
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3YTD,2013-01-01,2013-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23261700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23261700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4769900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4769900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18491800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7149500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5519000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,289200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12957700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5534100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,457800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,457800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5991900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1207300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4784600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4784600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4784600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,4.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.38
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1083900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q3TTM,2012-10-01,2013-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5929700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5929700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1165200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1165200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4764500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1867600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1330400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,63500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3261500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1503000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,11900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,11900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1514900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,308700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1206200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1206200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1206200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1077000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1086700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1077000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2,2013-04-01,2013-06-30,2013-07-26 11:57:41+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11531700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11531700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2323500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2323500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9208200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3519600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2678500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,85200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6283300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2924900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,541100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,541100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3466000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,711800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2754200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2754200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2754200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1077000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.54
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1086700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1077000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.54
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2YTD,2013-01-01,2013-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.98
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22932400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22932400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4775400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4775400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18157000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7254500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5484400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,342500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13081400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5075600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1277600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1277600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6353200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1445100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4908100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4908100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4908100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1077000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,4.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1086700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.45
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1077000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q2TTM,2012-07-01,2013-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5602000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5602000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1158300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1158300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4443700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1652000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1348100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,21700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3021800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1421900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,529200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,529200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1951100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,403100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1548000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1548000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1548000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1090100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.42
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1090100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.42
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1090100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.42
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1,2013-01-01,2013-03-31,2013-04-26 11:42:11+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22603400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22603400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4756900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4756900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17846500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7318000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5474700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,279000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13071700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4774800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1249200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1249200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6024000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1398500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4625500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4625500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4625500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1090100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,4.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1090100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.17
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1090100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2013.0,Q1TTM,2012-04-01,2013-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19615600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19615600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4932500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4932500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14683100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6620800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4933800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,468700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12023300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2659800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,340500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,340500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3000300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,609800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2390500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2390500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2390500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1069932000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.23
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1074286000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.23
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1072000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,FY,2014-01-01,2014-12-31,2017-02-21 15:32:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.23
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5121300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5121300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1253100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1253100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3868200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1799900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1290900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,401000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3491800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,376400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,137200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,137200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,513600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,85100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,428500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,428500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,428500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1069932000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1074286000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1072000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.4
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q4,2014-10-01,2014-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4875600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4875600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1267000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1267000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3608600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1672100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1338200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,36300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3046600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,562000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,93500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,93500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,655500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,154900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,500600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,500600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,500600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1069600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1074400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1065100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3,2014-07-01,2014-09-30,2015-10-30 15:07:28+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14494300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14494300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3679400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3679400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10814900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4820900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3642900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,67700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8531500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2283400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,203300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,203300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2486700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,524700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1962000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1962000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1962000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1069600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.83
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1074400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.83
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1065100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.83
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3YTD,2014-01-01,2014-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.47
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20303100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20303100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5065900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5065900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15237200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6774500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5175400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,103100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12053000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3184200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,212400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,212400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3396600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,707100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2689500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2689500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2689500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1069600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.51
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1074400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.51
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1065100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q3TTM,2013-10-01,2014-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.51
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9618700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9618700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2412400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2412400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7206300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3148800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2304700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,31400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5484900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1721400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,109800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,109800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1831200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,369800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1461400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1461400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1461400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1071700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.36
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1076400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.36
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1078700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.36
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2YTD,2014-01-01,2014-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.98
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21200100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21200100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4997000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4997000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16203100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6754800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5214600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,66800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12036200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4166900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,87600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,87600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4254500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,862500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3392000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3392000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3392000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1071700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.15
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1076400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.15
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1078700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2TTM,2013-07-01,2014-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.15
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4935600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4935600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1189700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1189700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3745900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1663900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1195400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2859300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,886600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,53800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,53800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,940400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,206900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,733500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,733500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,733500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1071700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1076400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1078700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q2,2014-04-01,2014-06-30,2015-07-30 16:17:28+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4683100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4683100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1222700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1222700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3460400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1484900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1109300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,31400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2625600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,834800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,56000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,56000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,890800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,162900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,727900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,727900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,727900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1072700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1075800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1070400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1,2014-01-01,2014-03-31,2014-04-28 14:28:31+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.49
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22194200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22194200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4972500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4972500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17221700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6958500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5349600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,130300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12438400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4783300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,45700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,45700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4829000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,964300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3864700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3864700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3864700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1072700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,3.59
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1075800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1070400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2014.0,Q1TTM,2013-04-01,2014-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.59
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19958700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19958700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5037200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5037200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14921500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6533000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5331400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,367700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12232100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2689400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,100600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,100600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2790000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,381600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2408400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2408400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2408400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061913000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.27
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065720000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.26
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1061000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,FY,2015-01-01,2015-12-31,2018-02-20 17:27:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.27
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5375600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5375600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1389200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1389200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3986400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1798400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1643200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,144900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3586500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,399900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,44700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,44700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,444600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-33800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,478400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,478400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,478400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061913000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.45
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065720000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.45
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1061000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.45
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q4,2015-10-01,2015-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,-1.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4959700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4959700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1236900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1236900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3722800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1575700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1143400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,42400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2761500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,961300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,86500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,86500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1047800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,248100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,799700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,799700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,799700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.75
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.75
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1066300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.75
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3,2015-07-01,2015-09-30,2016-10-28 12:02:04+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14583100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14583100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3648000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3648000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10935100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4734600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3688200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,222800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8645600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2289500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,55900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,55900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2345400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,415400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1930000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1930000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1930000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.82
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.81
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1066300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.82
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3YTD,2015-01-01,2015-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19704400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19704400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4901100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4901100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14803300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6534500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4979100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,623800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12137400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2665900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,193100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,193100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2859000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,500500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2358500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2358500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2358500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.22
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.21
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1066300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.22
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q3TTM,2014-10-01,2015-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.03
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4978700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4978700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1218400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1218400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3760300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1635400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1249500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,72400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2957300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,803000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-123300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-123300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,679700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,78900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,600800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,600800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,600800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.57
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.56
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1054000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.57
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2,2015-04-01,2015-06-30,2016-07-28 13:00:37+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9623400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9623400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2411100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2411100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7212300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3158900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2544800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,180400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5884100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1328200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-30600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-30600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1297600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,167300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1130300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1130300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1130300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.06
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1054000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2YTD,2015-01-01,2015-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19620300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19620300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4931200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4931200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14689100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6630900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5173900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,617700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12422500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2266600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,200100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,200100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2466700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,407300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2059400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2059400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2059400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1061700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.94
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1065600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.93
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1054000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.94
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q2TTM,2014-07-01,2015-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.02
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4644700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4644700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1192700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1192700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3452000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1523500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1295300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,108000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2926800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,525200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,92700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,92700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,617900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,88400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,529500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,529500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,529500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1064200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1067000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1059000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1,2015-01-01,2015-03-31,2016-04-29 13:26:48+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.5
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19577200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19577200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4902500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4902500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,14674700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6659400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5119800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,545300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12324500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2350200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,377200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,377200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2727400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,535300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2192100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2192100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2192100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1064200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1067000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1059000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2015.0,Q1TTM,2014-04-01,2015-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.01
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21222100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21222100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5710100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5710100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15512000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6528000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5340300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,382500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12250800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3261200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,112800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3374000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,636400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2737600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2737600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2737600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1058324000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.59
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1061825000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1057000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.59
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,FY,2016-01-01,2016-12-31,2019-02-19 10:41:31+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.05
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5760500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5760500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1521200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1521200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4239300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1866100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1547000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,147600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3560700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,678600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,213400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,213400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,892000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,120200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,771800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,771800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,771800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1058324000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.72
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1061825000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.73
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1057000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.72
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q4,2016-10-01,2016-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.52
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5191700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5191700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1400900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1400900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3790800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1565400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1236400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,45500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2847300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,943500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,27200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,27200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,970700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,192700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,778000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,778000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,778000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1057700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.74
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1060800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.73
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1051400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.74
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3,2016-07-01,2016-09-30,2017-10-27 11:53:10+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.51
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15461600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15461600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4188900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4188900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11272700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4661900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3793300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,234900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8690100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2582600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-100600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-100600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2482000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,516200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1965800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1965800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1965800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1057700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.87
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1060800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.85
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1051400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.87
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3YTD,2016-01-01,2016-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20837200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20837200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5578100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5578100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15259100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6460300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5436500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,379800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12276600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2982500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-55900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-55900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2926600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,482400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2444200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2444200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2444200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1057700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.32
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1060800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.3
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1051400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.32
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q3TTM,2015-10-01,2016-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.03
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5404800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5404800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1465000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1465000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3939800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1622600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1335900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,58000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3016500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,923300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,21200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,21200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,944500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,196800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,747700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,747700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,747700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1057700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.71
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1060100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.71
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1053100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.71
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2,2016-04-01,2016-06-30,2017-07-28 11:42:15+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.51
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10269900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10269900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2788000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2788000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7481900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3096500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2556900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,189400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5842800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1639100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-127800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-127800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1511300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,323500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1187800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1187800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1187800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1057700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1060100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1053100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2YTD,2016-01-01,2016-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.02
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20605200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20605200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5414100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5414100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15191100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6470600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5343500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,376700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12190800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3000300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3003700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,537800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2465900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2465900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2465900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1057700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1060100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.32
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1053100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q2TTM,2015-07-01,2016-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.02
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4865100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4865100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1323000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1323000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3542100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1473900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1221000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,131400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2826300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,715800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-149000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-149000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,566800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,126700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,440100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,440100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,440100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1059900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.42
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1063100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.41
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1047900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.42
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1,2016-01-01,2016-03-31,2017-05-01 11:49:54+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.51
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,20179100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,20179100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5167500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5167500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15011600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6483400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5257100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,391100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12131600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2880000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-141100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-141100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2738900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,419900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2319000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2319000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2319000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1059900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.19
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1063100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.17
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1047900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.19
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2016.0,Q1TTM,2015-04-01,2016-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.01
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19973800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19973800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4447700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4447700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15526100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5982400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6208800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1331600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13522800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2003300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,301500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,301500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2304800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2391200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-86400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-117700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-204100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-204100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1052023000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1052023000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1074200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,FY,2017-01-01,2017-12-31,2020-02-19 12:33:26+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3263200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3263200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-58200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-58200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3321400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1105800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1275800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,661200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3042800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,278600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,112900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,112900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,391500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1930700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1539200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-117700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1656900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1656900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1052023000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1052023000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.57
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1074200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.58
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q4,2017-10-01,2017-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.08
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5658000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5658000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1586300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1586300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4071700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1578500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1545000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,406500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3530000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,541700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,49900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,49900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,591600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,36000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,555600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,555600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,555600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1053400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1056000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1048300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3,2017-07-01,2017-09-30,2018-11-06 10:35:10+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.53
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16710600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16710600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4505900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4505900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12204700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4876600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4933000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,670400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10480000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1724700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,188600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,188600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1913300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,460500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1452800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1452800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1452800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1053400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.39
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1056000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.38
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1048300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.39
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3YTD,2017-01-01,2017-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.04
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22471100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22471100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6027100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6027100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16444000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6742700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6480000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,818000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14040700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2403300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,402000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,402000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2805300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,580700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2224600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2224600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2224600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1053400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1056000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1048300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.11
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q3TTM,2016-10-01,2017-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.56
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5824300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5824300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1571700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1571700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4252600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1730400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1272100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,50000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3052500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1200100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,60400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,60400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1260500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,252500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1008000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1008000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1008000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1055000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.96
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1057100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.95
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1050000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.96
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2,2017-04-01,2017-06-30,2018-07-25 16:48:39+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.52
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11052600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11052600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2919600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2919600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8133000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3298100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3388000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,263900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6950000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1183000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,138700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,138700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1321700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,424500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,897200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,897200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,897200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1055000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1057100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.85
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1050000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.86
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2YTD,2017-01-01,2017-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.04
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22004800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22004800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5841700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5841700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16163100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6729600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6171400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,457000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13358000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2805100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,379300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,379300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3184400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,737400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2447000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2447000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2447000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1055000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.32
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1057100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.31
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1050000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.32
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q2TTM,2016-07-01,2017-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5228300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5228300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1347900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1347900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3880400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1567700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2115900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,213900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3897500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,78300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,78300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,61200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,172000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-110800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-110800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-110800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1056300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1056300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1108000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1,2017-01-01,2017-03-31,2018-04-27 11:32:39+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,0.52
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21585300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21585300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5735000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5735000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15850300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6621800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6235200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,465000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13322000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2528300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,340100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,340100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2868400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,681700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2186700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2186700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2186700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1056300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1056300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1108000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2017.0,Q1TTM,2016-04-01,2017-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.06
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21493300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21493300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4681700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4681700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16811600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5975100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7035100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,266900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13277100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3534500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,145600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,145600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3680100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,529500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3150600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,81400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3232000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3232000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1027721000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.14
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1033667000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,3.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1029300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.14
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,FY,2018-01-01,2018-12-31,2020-02-19 12:33:26+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5637600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5637600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1129900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1129900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4507700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1693600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1721200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,192700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3612000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,895700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,35900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,35900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,931600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-189800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1121400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1125000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1125000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1027721000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.1
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1033667000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.1
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1029300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.1
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q4,2018-10-01,2018-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5306900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5306900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1152900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1152900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4154000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1457200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1310900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,42900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2811000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1343000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1341100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,247500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1093600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,55900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1149500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1149500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1020400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1026300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1017300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3,2018-07-01,2018-09-30,2019-10-25 11:54:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15855700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15855700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3551800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3551800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12303900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4281500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5313900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,74200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9665100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2638800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,109700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,109700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2748500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,719300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2029200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,77800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2107000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2107000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1020400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.04
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1026300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.03
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1017300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3YTD,2018-01-01,2018-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.04
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19118900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19118900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3493600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3493600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15625300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5387300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6589700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,735400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12707900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2917400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,222600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,222600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3140000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2650000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,490000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-39900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,450100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,450100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1020400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.46
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1026300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.46
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1017300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.46
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q3TTM,2017-10-01,2018-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.08
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5585000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5585000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1234300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1234300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4350700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1485600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2895500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-25500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4351100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,42100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,42100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,41700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,273300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-231600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-28300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-259900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-259900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1030200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1030200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1039600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2,2018-04-01,2018-06-30,2019-08-02 12:47:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10548800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10548800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2398900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2398900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8149900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2824300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4003000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,31300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6854100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1295800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,111600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,111600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1407400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,471800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,935600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,21900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,957500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,957500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1030200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.91
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1030200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.91
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1039600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2YTD,2018-01-01,2018-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.91
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19470000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19470000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3927000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3927000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15543000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5508600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6823800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1099000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13426900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2116100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,274400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,274400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2390500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2438500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-48000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-95800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-143800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-143800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1030200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1030200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1039600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q2TTM,2017-07-01,2018-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.08
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4963800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4963800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1164600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1164600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3799200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1338700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1107500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,56800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2503000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1296200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,69500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,69500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1365700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,198500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1167200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,50200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1217400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1217400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1048000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.16
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1049800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.16
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1049500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1,2018-01-01,2018-03-31,2019-05-02 14:09:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.16
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19709300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19709300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4264400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4264400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15444900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5753400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5200400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,1174500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12128300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3316600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,292700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,292700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3609300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2417700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1191600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-67500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1124100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1124100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,1048000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1049800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,1049500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.07
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2018.0,Q1TTM,2017-04-01,2018-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,1.6
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6114000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6114000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1282600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1282600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4831400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1698100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1581400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,151700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3431200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1400200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,262900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,262900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1663100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,167400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1495700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1495700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1495700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,931059000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,1.79
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,935684000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.77
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,931500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.79
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q4,2019-10-01,2019-12-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22319500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22319500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4721200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4721200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17598300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6213800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5834600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,575600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12624000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4974300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,291600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,291600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5265900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,628000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4637900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3680500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,8318400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,8318400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,931059000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,8.93
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,935684000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,8.89
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,931500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.93
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,FY,2019-01-01,2019-12-31,2020-02-19 12:33:26+00:00,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,16205500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,16205500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3438600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3438600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,12766900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4515700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4253200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,423900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9192800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3574100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,28700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,28700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3602800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,460600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3142200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3680500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6822700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6822700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,913900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,7.14
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,918500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,7.12
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,915300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3YTD,2019-01-01,2019-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,7.14
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21843100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21843100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4568500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4568500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17274600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6209300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5974400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,616600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12804800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4469800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,64600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,64600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4534400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,270800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4263600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3684100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7947700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7947700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,913900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,8.24
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,918500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,8.22
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,915300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.24
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3TTM,2018-10-01,2019-09-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5476600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5476600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1175000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1175000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4301600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1412300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1458600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,2870900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1430700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-24900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-24900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1405800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,151900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1253900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1253900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1253900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,913900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.37
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,918500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.37
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,915300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q3,2019-07-01,2019-09-30,2019-10-25 11:54:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.37
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10728900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10728900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2263600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2263600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8465300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3103400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2794600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,423900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6321900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2143400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,53600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,53600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2197000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,308700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1888300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3680500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5568800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5568800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,920800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,5.77
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,924600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,5.75
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,921700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2YTD,2019-01-01,2019-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,5.77
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21673400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21673400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4546400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4546400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17127000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6254200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5826700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,659500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12744900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4382100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,87600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,87600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4469700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,366400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4103300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3740000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7843300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7843300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,920800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,8.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,924600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,7.97
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,921700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,8.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2TTM,2018-07-01,2019-06-30,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5636700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5636700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1124900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1124900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4511800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1586300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1427200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3013500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1498300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-32400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-32400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1465900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,138700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1327200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1327200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1327200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,920800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.44
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,924600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.44
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,921700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q2,2019-04-01,2019-06-30,2019-08-02 12:47:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.44
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5092200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5092200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1138700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1138700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3953500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1517100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1367400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,423900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3308400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,645100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,86000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,86000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,731100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,170000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,561100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3680500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4241600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4241600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,979900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,4.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,984000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,4.31
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,979600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1,2019-01-01,2019-03-31,2020-05-01 09:46:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,4.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21621700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21621700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4655800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4655800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16965900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6153500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7295000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,634000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14082500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,2883400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,162100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,162100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3045500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,501000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2544500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,3711700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6256200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6256200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,979900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,6.31
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,984000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,6.28
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,979600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,6.31
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2019.0,Q1TTM,2018-04-01,2019-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.33
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,23087100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,23087100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4797600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4797600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18289500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6246300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5911600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,211600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12369500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5920000000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,294700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,294700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6214700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,681400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5533300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5533300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5533300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,908200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,6.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,911700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,6.18
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,910300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,6.2
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1TTM,2019-04-01,2020-03-31,,,cashdividendspershare,Cash Dividends to Common per Share,=,,usdpershare,2.68
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5859800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5859800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1215100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1215100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4644700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1549600000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1444400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,59900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,3053900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1590800000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,89100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,89100000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1679900000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,223400000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1456500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1456500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1456500000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,908200000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.6
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,911700000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.6
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,910300000.0
Eli Lilly and Co,LLY,FRDRIPF3EKNDJ2CQJL29,0000059478,2020.0,Q1,2020-01-01,2020-03-31,2020-05-01 09:46:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.6
